The MC4 receptor and control of appetite

British Journal of Pharmacology

Volumn 149, Issue 7, 2006, Pages 815-827

  Adan, R A H ^a   Tiesjema, B ^a   Hillebrand, J J G ^a   La Fleur, S E ^a   Kas, M J H ^a   De Krom, M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

AgRP; Feeding behaviour; MC4 receptor; Melanocortins; Obesity; POMC

Indexed keywords

ALPHA INTERMEDIN; AMYLIN; ANOREXIGENIC AGENT; BETA ENDORPHIN; BETA INTERMEDIN; CHOLECYSTOKININ; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CORTICOTROPIN RELEASING FACTOR; GALANIN; GHRELIN; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; LEPTIN; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 2 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR BLOCKING AGENT; MELANOCORTIN 4 RECEPTOR STIMULATING AGENT; MELANOCORTIN 5 RECEPTOR; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; NEUROPEPTIDE Y; NEUROTENSIN; OREXIN; PEPTIDE YY; PROTIRELIN; REDOX EFFECTOR FACTOR 1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROCORTIN;

BODY WEIGHT; BRAIN REGION; CALORIC INTAKE; DRUG RECEPTOR BINDING; DRUG TARGETING; FEEDING BEHAVIOR; FOOD INTAKE; GENE DELETION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HYPERINSULINEMIA; HYPERPHAGIA; HYPOTHALAMUS NUCLEUS; KNOCKOUT MOUSE; LEAN BODY WEIGHT; LENTIVIRUS VECTOR; LIPID DIET; NONHUMAN; OBESITY; PENIS ERECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THALAMUS MIDLINE NUCLEUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WILD TYPE;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; APPETITE REGULATION; BRAIN; DIET; ENERGY INTAKE; FEEDING BEHAVIOR; FOOD PREFERENCES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MELANOCORTINS; MICE; MICE, TRANSGENIC; MUTATION; NUTRITION PHYSIOLOGY; OBESITY; PRO-OPIOMELANOCORTIN; RECEPTOR, MELANOCORTIN, TYPE 3; RECEPTOR, MELANOCORTIN, TYPE 4; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 33845222715     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706929     Document Type: Review

References (153)

1. Adage T, Scheurink AJ, de Boer SF, de Vries K, Konsman JP, Kuipers F et al. (2001). Hypothalamic, metabolic, and behavioral responses to pharmacological inhibition of CNS melanocortin signaling in rats. J Neurosci 21: 3639-3645.
2. Adan RA, Gispen WH (1997). Brain melanocortin receptors: from cloning to function. Peptides 18: 1279-1287.
3. Andersen GN, Hagglund M, Nagaeva O, Frangsmyr L, Petrovska R, Mincheva-Nilsson L et al. (2005). Quantitative measurement of the levels of melanocortin receptor subtype 1, 2, 3 and 5 and pro-opiomelanocortin peptide gene expression in subsets of human peripheral blood leucocytes. Scand J Immunol 61: 279-284.
4. Argyropoulos G, Rankinen T, Bai F, Rice T, Province MA, Leon AS et al. (2003). The agouti-related protein and body fatness in humans. Int J Obes Relat Metab Disord 27: 276-280.
5. Bakshi RK, Hong Q, Tang R, Kalyani RN, Macneil T, Weinberg DH et al. (2006). Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands. Bioorg Med Chem Lett 16: 1130-1133.
6. Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T et al. (2005). Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123: 493-505.
7. Banno R, Arima H, Sato I, Hayashi M, Goto M, Sugimura Y et al. (2004). The melanocortin agonist melanotan II increases insulin sensitivity in OLETF rats. Peptides 25: 1279-1286.
8. Barsh GS, Farooqi IS, O'Rahilly S (2000). Genetics of body-weight regulation. Nature 404: 644-651.
9. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL et al. (2002). Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650-654.
10. Benoit SC, Clegg DJ, Barrera JG, Seeley RJ, Woods SC (2003). Learned meal initiation attenuates the anorexic effects of the melanocortin agonist MTII. Diabetes 52: 2684-2688.
11. Berthoud HR (2004). Mind versus metabolism in the control of food intake and energy balance. Physiol Behav 81: 781-793.
12. Bhardwaj R, Becher E, Mahnke K, Hartmeyer M, Schwarz T, Scholzen T et al. (1997). Evidence for the differential expression of the functional alpha-melanocyte-stimulating hormone receptor MC-1 on human monocytes. J Immunol 158: 3378-3384.
13. Biebermann H, Castaneda TR, van Landeghem F, von Deimling A, Escher F, Brabant G et al. (2006). A role for beta-melanocyte-stimulating hormone in human body-weight regulation. Cell Metab 3: 141-146.
14. Bluher S, Ziotopoulou M, Bullen Jr JW, Moschos SJ, Ungsunan L, Kokkotou E et al. (2004). Responsiveness to peripherally administered melanocortins in lean and obese mice. Diabetes 53: 82-90.
15. Blundell JE, Gillett A (2001). Control of food intake in the obese. Obes Res 9 (Suppl 4): 263S-270S.
16. Boss O, Bergenhem N (2006). Adipose targets for obesity drug development. Expert Opin Ther Targets 10: 119-134.
17. Boston BA (1999). The role of melanocortins in adipocyte function. Ann NY Acad Sci 885: 75-84.
18. Brief DJ, Davis JD (1984). Reduction of food intake and body weight by chronic intraventricular insulin infusion. Brain Res Bull 12: 571-575.
19. Butler AA (2006). The melanocortin system and energy balance. Peptides 27: 281-290.
20. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J et al. (2000). A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141: 3518-3521.
21. Butler AA, Marks DL, Fan W, Kuhn CM, Bartolome M, Cone RD (2001). Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. Nat Neurosci 4: 605-611.
22. Catania A, Gatti S, Colombo G, Lipton JM (2004). Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 56: 1-29.
23. Challis BG, Pritchard LE, Creemers JW, Delplanque J, Keogh JM, Luan J et al. (2002). A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. Hum Mol Genet 11: 1997-2004.
24. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H et al. (2000a). Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 26: 97-102.
25. Chen AS, Metzger JM, Trumbauer ME, Guan XM, Yu H, Frazier EG et al. (2000b). Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res 9: 145-154.
26. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ et al. (1996). Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491-495.
27. Clegg DJ, Benoit SC, Air EL, Jackman A, Tso P, D'Alessio D et al. (2003). Increased dietary fat attenuates the anorexic effects of intracerebroventricular injections of MTII. Endocrinology 144: 2941-2946.
28. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D et al. (1998). A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392: 398-401.
29. Cone RD (2005). Anatomy and regulation of the central melanocortin system. Nat Neurosci 8: 571-578.
30. Cowley MA, Pronchuk N, Fan W, Dinulescu DM, Colmers WF, Cone RD (1999). Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 24: 155-163.
31. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 16: 51-59.
32. Erlanson-Albertsson C (2005). How palatable food disrupts appetite regulation. Basic Clin Pharmacol Toxicol 97: 61-73.
33. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD (1997). Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385: 165-168.
34. Fan W, Ellacott KL, Halatchev IG, Takahashi K, Yu P, Cone RD (2004). Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system. Nat Neurosci 7: 335-336.
35. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S (2003). Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348: 1085-1095.
36. Farooqi IS, O'Rahilly S (2005). Monogenic obesity in humans. Annu Rev Med 56: 443-458.
37. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G et al. (2000). Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 106: 271-279.
38. Fathi Z, Iben LG, Parker EM (1995). Cloning, expression, and tissue distribution of a fifth melanocortin receptor subtype. Neurochem Res 20: 107-113.
39. Fekete C, Marks DL, Sarkar S, Emerson CH, Rand WM, Cone RD et al. (2004). Effect of agouti-related protein (AGRP) in regulation of the hypothalamic-pituitary-thyroid (HPT) axis in the MC3-R KO mouse. Endocrinology 145: 4816-4821.
40. Friedman JM, Halaas JL (1998). Leptin and the regulation of body weight in mammals. Nature 395: 763-770.
41. Gantz I, Fong TM (2003). The melanocortin system. Am J Physiol Endocrinol Metab 284: E468-E474.
42. Getting SJ, Gibbs L, Clark AJ, Flower RJ, Perretti M (1999). POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation. J Immunol 162: 7446-7453.
43. Giraudo SQ, Billington CJ, Levine AS (1998). Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands. Brain Res 809: 302-306.
44. Gispen WH, Wiegant VM, Greven HM, De Wied D (1975). The induction of excessive grooming in the rat by intraventricular application of peptides derived from ACTH: structure-activity studies. Life Sci 17: 645-652.
45. Gomori A, Ishihara A, Ito M, Mashiko S, Matsushita H, Yumoto M et al. (2003). Chronic intracerebroventricular infusion of MCH causes obesity in mice. Melanin-concentrating hormone. Am J Physiol Endocrinol Metab 284: E583-E588.
46. Griffon N, Mignon V, Facchinetti P, Diaz J, Schwartz JC, Sokoloff P (1994). Molecular cloning and characterization of the rat fifth melanocortin receptor. Biochem Biophys Res Commun 200: 1007-1014.
47. Grill HJ, Ginsberg AB, Seeley RJ, Kaplan JM (1998). Brainstem application of melanocortin receptor ligands produces long-lasting effects on feeding and body weight. J Neurosci 18: 10128-10135.
48. Hagan MM, Rushing PA, Benoit SC, Woods SC, Seeley RJ (2001). Opioid receptor involvement in the effect of AgRP-(83-132) on food intake and food selection. Am J Physiol Regul Integr Comp Physiol 280: R814-R821.
49. Hagan MM, Rushing PA, Pritchard LM, Schwartz MW, Strack AM, Van der Ploeg LH et al. (2000). Long-term orexigenic effects of AgRP-(83-132) involve mechanisms other than melanocortin receptor blockade. Am J Physiol Regul Integr Comp Physiol 279: R47-R52.
50. Hagan MM, Rushing PA, Schwartz MW, Yagaloff KA, Burn P, Woods SC et al. (1999). Role of the CNS melanocortin system in the response to overfeeding. J Neurosci 19: 2362-2367.
51. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM (1997). Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 94: 8878-8883.
52. Halatchev IG, Ellacott KL, Fan W, Cone RD (2004). Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145: 2585-2590.
53. Hanada R, Nakazato M, Matsukura S, Murakami N, Yoshimatsu H, Sakata T (2000). Differential regulation of melanin-concentrating hormone and orexin genes in the agouti-related protein/melanocortin-4 receptor system. Biochem Biophys Res Commun 268: 88-91.
54. Harris M, Aschkenasi C, Elias CF, Chandrankunnel A, Nillni EA, Bjoorbaek C et al. (2001). Transcriptional regulation of the thyrotropin-releasing hormone gene by leptin and melanocortin signaling. J Clin Invest 107: 111-120.
55. Haskell-Luevano C, Monck EK (2001). Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor. Regul Peptides 99: 1-7.
56. Haynes AC, Jackson B, Overend P, Buckingham RE, Wilson S, Tadayyon M et al. (1999). Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides 20: 1099-1105.
57. Heijboer AC, van den Hoek AM, Pijl H, Voshol PJ, Havekes LM, Romijn JA et al. (2005). Intracerebroventricular administration of melanotan II increases insulin sensitivity of glucose disposal in mice. Diabetologia 48: 1621-1626.
58. Hinney A, Bettecken T, Tarnow P, Brumm H, Reichwald K, Lichtner P et al. (2006). Prevalence, spectrum, and functional characterization of melanocortin-4 receptor gene mutations in a representative population-based sample and obese adults from Germany. J Clin Endocrinol Metab 91: 1761-1769.
59. Hirsch MD, O'Donohue TL, Wilson R, Sawyer TK, Hruby VJ, Hadley ME et al. (1984). Structural and conformational modifications of alpha-MSH/ACTH4-10 provide melanotropin analogues with highly potent behavioral activities. Peptides 5: 1197-1201.
60. Holder JR, Haskell-Luevano C (2004). Melanocortin ligands: 30 years of structure-activity relationship (SAR) studies. Med Res Rev 24: 325-356.
61. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR et al. (1997). Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131-141.
62. Jegou S, Boutelet I, Vaudry H (2000). Melanocortin-3 receptor mRNA expression in pro-opiomelanocortin neurones of the rat arcuate nucleus. J Neuroendocrinol 12: 501-505.
63. Jonsson L, Skarphedinsson JO, Skuladottir GV, Watanobe H, Schioth HB (2002). Food conversion is transiently affected during 4-week chronic administration of melanocortin agonist and antagonist in rats. J Endocrinol 173: 517-523.
64. Kas MJ, Tiesjema B, van Dijk G, Garner KM, Barsh GS, Brake OT et al. (2004). Induction of brain-region-specific forms of obesity by agouti. J Neurosci 24: 10176-10181.
65. Kask A, Rago L, Wikberg JE, Schioth HB (2000). Differential effects of melanocortin peptides on ingestive behaviour in rats: evidence against the involvement of MC(3) receptor in the regulation of food intake. Neurosci Lett 283: 1-4.
66. Kask A, Schioth HB (2000). Tonic inhibition of food intake during inactive phase is reversed by the injection of the melanocortin receptor antagonist into the paraventricular nucleus of the hypothalamus and central amygdala of the rat. Brain Res 887: 460-464.
67. Kim MS, Rossi M, Abusnana S, Sunter D, Morgan DG, Small CJ et al. (2000). Hypothalamic localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating hormone. Diabetes 49: 177-182.
68. Kinzig KP, Scott KA, Hyun J, Bi S, Moran TH (2005). Altered hypothalamic signaling and responses to food deprivation in rats fed a low-carbohydrate diet. Obes Res 13: 1672-1682.
69. Kishi T, Aschkenasi CJ, Lee CE, Mountjoy KG, Saper CB, Elmquist JK (2003). Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J Comp Neurol 457: 213-235.
70. Koegler FH, Schaffhauser RO, Mynatt RL, York DA, Bray GA (1999). Macronutrient diet intake of the lethal yellow agouti (Ay/a) mouse. Physiol Behav 67: 809-812.
71. Krahn DD, Gosnell BA, Majchrzak MJ (1990). The anorectic effects of CRH and restraint stress decrease with repeated exposures. Biol Psychiatry 27: 1094-1102.
72. Kral TV (2006). Effects on hunger and satiety, perceived portion size and pleasantness of taste of varying the portion size of foods: a brief review of selected studies. Appetite 46: 103-105.
73. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A (1998). Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19: 155-157.
74. Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE et al. (2003). Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 88: 4633-4640.
75. Larsen LH, Echwald SM, Sorensen TI, Andersen T, Wulff BS, Pedersen O (2005). Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity. J Clin Endocrinol Metab 90: 219-224.
76. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI et al. (1996). Abnormal splicing of the leptin receptor in diabetic mice. Nature 379: 632-635.
77. Lee YS, Challis BG, Thompson DA, Yeo GS, Keogh JM, Madonna ME et al. (2006). A POMC variant implicates beta-melanocytestimulating hormone in the control of human energy balance. Cell Metab 3: 135-140.
78. Leiba H, Garty NB, Schmidt-Sole J, Piterman O, Azrad A, Salomon Y (1990). The melanocortin receptor in the rat lacrimal gland: a model system for the study of MSH (melanocyte stimulating hormone) as a potential neurotransmitter. Eur J Pharmacol 181: 71-82.
79. Levine AS, Kneip J, Grace M, Morley JE (1983). Effect of centrally administered neurotensin on multiple feeding paradigms. Pharmacol Biochem Behav 18: 19-23.
80. Lipton JM, Catania A (1998). Mechanisms of antiinflammatory action of the neuroimmunomodulatory peptide alpha-MSH. Ann NY Acad Sci 840: 373-380.
81. Loos RJ, Rankinen T, Rice T, Rao DC, Leon AS, Skinner JS et al. (2005). Two ethnic-specific polymorphisms in the human agouti-related protein gene are associated with macronutrient intake. Am J Clin Nutr 82: 1097-1101.
82. Lu XY, Barsh GS, Akil H, Watson SJ (2003). Interaction between alpha-melanocyte-stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-pituitary-adrenal responses. J Neurosci 23: 7863-7872.
83. Lubrano-Berthelier C, Dubern B, Lacorte JM, Picard F, Shapiro A, Zhang S et al. (2006). Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metab 91: 1811-1818.
84. Lubrano-Berthelier C, Durand E, Dubern B, Shapiro A, Dazin P, Weill J et al. (2003). Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet 12: 145-153.
85. Luquet S, Perez FA, Hnasko TS, Palmiter RD (2005). NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science 310: 683-685.
86. MacKenzie RG (2006). Obesity-associated mutations in the human melanocortin-4 receptor gene. Peptides 27: 395-403.
87. Makimura H, Mizuno TM, Mastaitis JW, Agami R, Mobbs CV (2002). Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci 3: 18.
88. Marks DL, Hruby V, Brookhart G, Cone RD (2006). The regulation of food intake by selective stimulation of the type 3 melanocortin receptor (MC3R). Peptides 27: 259-264.
89. Marsh DJ, Hollopeter G, Huszar D, Laufer R, Yagaloff KA, Fisher SL et al. (1999a). Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet 21: 119-122.
90. Marsh DJ, Miura GI, Yagaloff KA, Schwartz MW, Barsh GS, Palmiter RD (1999b). Effects of neuropeptide Y deficiency on hypothalamic agouti-related protein expression and responsiveness to melanocortin analogues. Brain Res 848: 66-77.
91. Mayfield DK, Brown AM, Page GP, Garvey WT, Shriver MD, Argyropoulos G (2001). A role for the agouti-related protein promoter in obesity and type 2 diabetes. Biochem Biophys Res Commun 287: 568-573.
92. McMinn JE, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW (2000). Effect of intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos induction, and neuropeptide expression. Am J Physiol Regul Integr Comp Physiol 279: R695-R703.
93. Mizuno TM, Kleopoulos SP, Bergen HT, Roberts JL, Priest CA, Mobbs CV (1998). Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting and (corrected) in ob/ob and db/db mice, but is stimulated by leptin. Diabetes 47: 294-297.
94. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ et al. (1997). Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387: 903-908.
95. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD (1994). Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 8: 1298-1308.
96. Muceniece R, Zvejniece L, Liepinsh E, Kirjanova O, Baumane L, Petrovska R et al. (2006). The MC(3) receptor binding affinity of melanocortins correlates with the nitric oxide production inhibition in mice brain inflammation model. Peptides 27: 1443-1450.
97. Nicholson JR, Kohler G, Schaerer F, Senn C, Weyermann P, Hofbauer KG (2006). Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J Pharmacol Exp Ther 317: 771-777.
98. Nijenhuis WA, Garner KM, van Rozen RJ, Adan RA (2003). Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity. J Biol Chem 278: 22939-22945.
99. Nijenhuis WA, Oosterom J, Adan RA (2001). AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol Endocrinol 15: 164-171.
100. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I et al. (1997). Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278: 135-138.
101. Qian S, Chen H, Weingarth D, Trumbauer ME, Novi DE, Guan X et al. (2002). Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol Cell Biol 22: 5027-5035.
102. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA et al. (2001). Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98: 2843-2848.
103. Robbins LS, Nadeau JH, Johnson KR, Kelly MA, Roselli-Rehfuss L, Baack E et al. (1993). Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72: 827-834.
104. Rohner-Jeanrenaud F, Craft LS, Bridwell J, Suter TM, Tinsley FC, Smiley DL et al. (2002). Chronic central infusion of cocaine- and amphetamine-regulated transcript (CART 55-102): effects on body weight homeostasis in lean and high-fat-fed obese rats. Int J Obes Relat Metab Disord 26: 143-149.
105. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB et al. (1993). Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 90: 8856-8860.
106. Rossi M, Kim MS, Morgan DG, Small CJ, Edwards CM, Sunter D et al. (1998). A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology 139: 4428-4431.
107. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC (2000). Amylin: a novel action in the brain to reduce body weight. Endocrinology 141: 850-853.
108. Samama P, Rumennik L, Grippo JF (2003). The melanocortin receptor MCR4 controls fat consumption. Regul Peptides 113: 85-88.
109. Santini F, Maffei M, Ceccarini G, Pelosini C, Scartabelli G, Rosellini V et al. (2004). Genetic screening for melanocortin-4 receptor mutations in a cohort of Italian obese patients: description and functional characterization of a novel mutation. J Clin Endocrinol Metab 89: 904-908.
110. Schick RR, Stevens CW, Yaksh TL, Go VL (1988). Chronic intraventricular administration of cholecystokinin octapeptide (CCK-8) suppresses feeding in rats. Brain Res 448: 294-298.
111. Schioth HB, Chhajlani V, Muceniece R, Klusa V, Wikberg JE (1996). Major pharmacological distinction of the ACTH receptor from other melanocortin receptors. Life Sci 59: 797-801.
112. Schwartz MW, Seeley RJ, Woods SC, Weigle DS, Campfield LA, Burn P et al. (1997). Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 46: 2119-2123.
113. Seeley RJ, Burklow ML, Wilmer KA, Matthews CC, Reizes O, McOsker CC et al. (2005). The effect of the melanocortin agonist, MT-II, on the defended level of body adiposity. Endocrinology 146: 3732-3738.
114. Shaw AM, Irani BG, Moore MC, Haskell-Luevano C, Millard WJ (2005). Ghrelin-induced food intake and growth hormone secretion are altered in melanocortin 3 and 4 receptor knockout mice. Peptides 26: 1720-1727.
115. Small CJ, Kim MS, Stanley SA, Mitchell JR, Murphy K, Morgan DG et al. (2001). Effects of chronic central nervous system administration of agouti-related protein in pair-fed animals. Diabetes 50: 248-254.
116. Small CJ, Liu YL, Stanley SA, Connoley IP, Kennedy A, Stock MJ et al. (2003). Chronic CNS administration of agouti-related protein (Agrp) reduces energy expenditure. Int J Obes Relat Metab Disord 27: 530-533.
117. Smart JL, Tolle V, Low MJ (2006). Glucocorticoids exacerbate obesity and insulin resistance in neuron-specific proopiomelanocort-indeficient mice. J Clin Invest 116: 495-505.
118. Smith BK, York DA, Bray GA (1994). Chronic cerebroventricular galanin does not induce sustained hyperphagia or obesity. Peptides 15: 1267-1272.
119. Srinivasan S, Lubrano-Berthelier C, Govaerts C, Picard F, Santiago P, Conklin BR et al. (2004). Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest 114: 1158-1164.
120. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF (1986). Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 7: 1189-1192.
121. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ (2005). A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 102: 13212-13217.
122. Ste Marie L, Miura GI, Marsh DJ, Yagaloff K, Palmiter RD (2000). A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc Natl Acad Sci USA 97: 12339-12344.
123. Strubbe JH, Woods SC (2004). The timing of meals. Psychol Rev 111: 128-141.
124. Sutton GM, Duos B, Patterson LM, Berthoud HR (2005). Melanocortinergic modulation of cholecystokinin-induced suppression of feeding through extracellular signal-regulated kinase signaling in rat solitary nucleus. Endocrinology 146: 3739-3747.
125. Thody AJ, Cooper MF, Bowden PE, Meddis D, Shuster S (1976). Effect of alpha-melanocyte-stimulating hormone and testosterone on cutaneous and modified sebaceous glands in the rat. J Endocrinol 71: 279-288.
126. Tian X, Field T, Mazur AW, Ebetino FH, Wos JA, Crossdoersen D et al. (2005). Design, synthesis, and evaluation of proline based melanocortin receptor ligands. Bioorg Med Chem Lett 15: 2819-2823.
127. Todorovic A, Haskell-Luevano C (2005). A review of melanocortin receptor small molecule ligands. Peptides 26: 2026-2036.
128. Tsujii S, Bray GA (1989). Acetylation alters the feeding response to MSH and beta-endorphin. Brain Res Bull 23: 165-169.
129. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P (2000). Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106: 253-262.
130. Van der Ploeg LH, Martin WJ, Howard AD, Nargund RP, Austin CP, Guan X et al. (2002). A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA 99: 11381-11386.
131. Vaughan CH, Moore MC, Haskell-Luevano C, Rowland NE (2005). Meal patterns and foraging in melanocortin receptor knockout mice. Physiol Behav 84: 129-133.
132. Versteeg DH, Van Bergen P, Adan RA, de Wildt DJ (1998). Melanocortins and cardiovascular regulation. Eur J Pharmacol 360: 1-14.
133. Vijayan E, McCann SM (1977). Suppression of feeding and drinking activity in rats following intraventricular injection of thyrotropin releasing hormone (TRH). Endocrinology 100: 1727-1730.
134. Vrinten DH, Kalkman CJ, Adan RA, Gispen WH (2001). Neuropathic pain: a possible role for the melanocortin system? Eur J Pharmacol 429: 61-69.
135. Wessells H, Blevins JE, Vanderah TW (2005). Melanocortinergic control of penile erection. Peptides 26: 1972-1977.
136. Wikberg JE (1999). Melanocortin receptors: perspectives for novel drugs. Eur J Pharmacol 375: 295-310.
137. Wikberg JE, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C et al. (2000). New aspects on the melanocortins and their receptors. Pharmacol Res 42: 393-420.
138. Williams DL, Grill HJ, Weiss SM, Baird JP, Kaplan JM (2002). Behavioral processes underlying the intake suppressive effects of melanocortin 3/4 receptor activation in the rat. Psychopharmacology (Berl) 161: 47-53.
139. Williams DL, Kaplan JM, Grill HJ (2000). The role of the dorsal vagal complex and the vagus nerve in feeding effects of melanocortin-3/4 receptor stimulation. Endocrinology 141: 1332-1337.
140. Wirth MM, Giraudo SQ (2000). Agouti-related protein in the hypothalamic paraventricular nucleus: effect on feeding. Peptides 21: 1369-1375.
141. Wirth MM, Giraudo SQ (2001). Effect of agouti-related protein delivered to the dorsomedial nucleus of the hypothalamus on intake of a preferred versus a non-preferred diet. Brain Res 897: 169-174.
142. Wirth MM, Olszewski PK, Yu C, Levine AS, Giraudo SQ (2001). Paraventricular hypothalamic alpha-melanocyte-stimulating hormone and MTII reduce feeding without causing aversive effects. Peptides 22: 129-134.
143. Woods SC, D'Alessio DA, Tso P, Rushing PA, Clegg DJ, Benoit SC et al. (2004). Consumption of a high-fat diet alters the homeostatic regulation of energy balance. Physiol Behav 83: 573-578.
144. Wortley KE, Anderson KD, Yasenchak J, Murphy A, Valenzuela D, Diano S et al. (2005). Agouti-related protein-deficient mice display an age-related lean phenotype. Cell Metab 2: 421-427.
145. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA et al. (2001). Ghrelin causes hyperphagia and obesity in rats. Diabetes 50: 2540-2547.
146. Xia Y, Wikberg JE, Chhajlani V (1995). Expression of melanocortin 1 receptor in periaqueductal gray matter. NeuroReport 6: 2193-2196.
147. Xu AW, Kaelin CB, Morton GJ, Ogimoto K, Stanhope K, Graham J et al. (2005). Effects of hypothalamic neurodegeneration on energy balance. PLoS Biol 3: e415.
148. Yang YK, Ollmann MM, Wilson BD, Dickinson C, Yamada T, Barsh GS et al. (1997). Effects of recombinant agouti-signaling protein on melanocortin action. Mol Endocrinol 11: 274-280.
149. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U (1999). Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5: 1066-1070.
150. Yeo GS, Lank EJ, Farooqi IS, Keogh J, Challis BG, O'Rahilly S (2003). Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet 12: 561-574.
151. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994). Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432.
152. Zheng H, Corkern MM, Crousillac SM, Patterson LM, Phifer CB, Berthoud HR (2002). Neurochemical phenotype of hypothalamic neurons showing Fos expression 23 h after intracranial AgRP. Am J Physiol Regul Integr Comp Physiol 282: R1773-R1781.
153. Zheng H, Patterson LM, Phifer CB, Berthoud HR (2005). Brain stem melanocortinergic modulation of meal size and identification of hypothalamic POMC projections. Am J Physiol Regul Integr Comp Physiol 289: R247-R258.